- Home
- LPCN vs RAPT Comparison
LPCN vs RAPT Comparison
Compare LPCN & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- RAPT
- Stock Information
- Founded
- LPCN 1997
- RAPT 2015
- Country
- LPCN United States
- RAPT United States
- Employees
- LPCN N/A
- RAPT N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- RAPT Health Care
- Exchange
- LPCN Nasdaq
- RAPT Nasdaq
- Market Cap
- LPCN 36.8M
- RAPT 30.8M
- IPO Year
- LPCN N/A
- RAPT 2019
- Fundamental
- Price
- LPCN $4.87
- RAPT $0.83
- Analyst Decision
- LPCN Strong Buy
- RAPT Hold
- Analyst Count
- LPCN 1
- RAPT 10
- Target Price
- LPCN $10.00
- RAPT $5.00
- AVG Volume (30 Days)
- LPCN 33.5K
- RAPT 393.6K
- Earning Date
- LPCN 11-07-2024
- RAPT 11-12-2024
- Dividend Yield
- LPCN N/A
- RAPT N/A
- EPS Growth
- LPCN N/A
- RAPT N/A
- EPS
- LPCN N/A
- RAPT N/A
- Revenue
- LPCN $7,922,926.00
- RAPT N/A
- Revenue This Year
- LPCN N/A
- RAPT N/A
- Revenue Next Year
- LPCN N/A
- RAPT N/A
- P/E Ratio
- LPCN N/A
- RAPT N/A
- Revenue Growth
- LPCN N/A
- RAPT N/A
- 52 Week Low
- LPCN $2.44
- RAPT $0.79
- 52 Week High
- LPCN $11.79
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- LPCN 47.54
- RAPT 32.23
- Support Level
- LPCN $4.68
- RAPT $0.79
- Resistance Level
- LPCN $5.28
- RAPT $0.93
- Average True Range (ATR)
- LPCN 0.36
- RAPT 0.10
- MACD
- LPCN -0.01
- RAPT 0.00
- Stochastic Oscillator
- LPCN 44.44
- RAPT 7.90
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.